---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-106529"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:26:59.509002+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xenon Q2 net loss $84.7M; azetukalner Phase 3 X-TOLE2 enrollment complete, topline early 2026

## Summary
- Net loss $84.7M vs $57.9M Q2 2024; R&D expenses rose to $75.0M from $49.7M on azetukalner trials.
- Phase 3 X-TOLE2 (focal seizures) patient recruitment complete; topline data expected early 2026.
- Phase 1 studies underway for XEN1120 (Kv7) and XEN1701 (Nav1.7) pain candidates.
- Darren Cline appointed Chief Commercial Officer to lead commercial build for azetukalner launch.
- Cash $624.8M as of June 30, 2025; funding expected into 2027.

## SEC filing metadata
- accession: 0000950170-25-106529
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000095017025106529/0000950170-25-106529-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000095017025106529/xene-20250811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-106529
- JSON: https://secwatch.observer/filing/0000950170-25-106529.json
- Plain text: https://secwatch.observer/filing/0000950170-25-106529.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.